Blackhole_1987 Posted - 3 hours ago

$CLNN it is heading to below $1 then reverse split. Rinse and repeat.

Blackhole_1987 Posted - 3 hours ago

$CLNN institutional holding is below 5% so it looks like they dumped at high to retails.

Blackhole_1987 Posted - 3 hours ago

$CLNN I knew paid pumpers will come up with this post.

Takeover24 Posted - 4 hours ago

$CLNN Would love to know who is selling today? Perhaps some tax loss selling? Just seems odd to get the positive FDA news that we got yet for the stock to trade down like it is a week later. And yes, I get the need to $$$ but this is still surprising to be honest.

neuroinvestor3 Posted - 4 hours ago

$CLNN tax loss selling and/or dilution event as our early X-mass present today.

Blackhole_1987 Posted - 5 hours ago

$CLNN all paid pumpers have disappeared. They will reappear when it slightly goes up. Typical paid pumpers.

Blackhole_1987 Posted - 1 day ago

$CLNN

Mulhollandr Posted - 1 day ago

$CLNN good days are ahead. Current price action is garbage.

Blackhole_1987 Posted - 1 day ago

$CLNN a typical paid pumper post with some facts.

Blackhole_1987 Posted - 1 day ago

$CLNN Expecting a huge dilution like 100% as happened with $DTIL garbage.

Mulhollandr Posted - 1 day ago

$CLNN wtf

neuroinvestor3 Posted - 1 day ago

$CLNN

neuroinvestor3 Posted - 1 day ago

$CLNN

josh77 Posted - 1 day ago

$CLNN In over 700 patient years of use of CNM-Au8, no significant safety concerns or safety trends have been identified. No serious adverse events (SAEs) have been identified as related to CNM-Au8 treatment by any investigator to date.

josh77 Posted - 1 day ago

$CLNN “We are incredibly grateful for the FDA’s willingness to consider how the available data from our expanded access programs may be able to support the existing clinical study data to allow for the review of an application for approval of CNM-Au8 for ALS via an accelerated regulatory pathway, and for the valuable feedback we have received to date,” said Rob Etherington, President and CEO of Clene. “Together with the survival and supportive biomarker data generated thus far, the drug’s benign safety profile, and the emerging EAP NfL data, we look forward to continued discussions with the Agency. Clene plans to include the additional data in an NDA submission under the accelerated approval pathway in mid-2025. We remain dedicated to the ALS community and honored to help critically ill patients and their families.”

Woodman7 Posted - 3 days ago

@Takeover24 @Nature175 - agree. This company is getting more and more press and the stock will likely benefit as we go thru the process. $CLNN

Blackhole_1987 Posted - 4 days ago

$CLNN Pump and dump garbage. Next year this company will go extinct.

NetworkNewsWire Posted - 4 days ago

New Technology Programs Immune Cells to Combat Brain Cancer, MS $CLNN https://ibn.fm/iTDiF #biomedstocks #AI

neuroinvestor3 Posted - 4 days ago

$CLNN while just over half of drugs make it to market after a phase 3 trial, this one is going to succeed. Excellent safety profile, proven efficacy data compiled by expert 3rd parties, and leadership/BOD with deep pockets. The $42m grant from the NIH also helps build confidence and if the EAP demand signal from PALS increases, we can expect additional federal funding or private foundation $ affiliated with Synapticure/Healey, etc. Would be nice for the NMSS to contribute funds for expanding the REPAIR-MS EAP.

Woodman7 Posted - 4 days ago

@Mulhollandr - the recent press is hopefully giving more people exposure to the stock. $CLNN

Mulhollandr Posted - 4 days ago

$CLNN that’s right, slow and steady wins the race. 🤞🏼🤞🏼🍀🍀

Nature175 Posted - 4 days ago

$CLNN Considering they will need some money soon, are people holding or cashing out now? Another 6 months before any significant news most likely. Not sure why this would be a good hold.... Sell now and buy back in a few months?

Takeover24 Posted - 4 days ago

@cascada @mrpsny One could reasonably speculate that the various potential partners that they have been talking to have been waiting to see the outcome of the FDA meeting on AA. One could further reasonably speculate that the written guidance received by $CLNN will be viewed as a very positive development by these potential partners and that there is now a greater likelihood of management executing such a deal than before such guidance. It also does not take a giant logical leap to deduce that the small offering they just did was simply a bridge to give them time to get the larger and more comprehensive funding deal done. We are sitting on a sleeping giant right now. But once the funding overhang is removed, the giant will be awaken.

Mulhollandr Posted - 5 days ago

$CLNN more please! https://www.neurologylive.com/view/clene-receives-fda-guidance-accelerated-approval-pathway-cnm-au8-als-plans-further-biomarker-analysis

Blackhole_1987 Posted - 5 days ago

$CLNN this analyst target is a joke. What might have caused them to reduce the target price by $3. What would be their timeline?. 2030?. Cheaters.

Blackhole_1987 Posted - 5 days ago

$CLNN another huge dilution in near future. A complete garbage. Retailers stay away from this garbage for some time.

BooBooBio Posted - 5 days ago

$CLNN when do you think the additional raise is going to happen ? Jan, Feb?

mrpsny Posted - 5 days ago

$CLNN IF they can provide the FDA the data they want, things look positive. But they're set to burn through all the cash long before this. Interesting. Watching and waiting to see how this plays out.

Mulhollandr Posted - 5 days ago

$CLNN NEED https://www.biospace.com/press-releases/fda-provides-roadmap-for-accelerated-approval-pathway-through-submission-of-additional-cnm-au8-biomarker-data-in-als

Mulhollandr Posted - 5 days ago

$CLNN MORE https://www.manilatimes.net/2024/12/10/tmt-newswire/globenewswire/fda-provides-roadmap-for-accelerated-approval-pathway-through-submission-of-additional-cnm-au8-biomarker-data-in-als/2019402